Pharmaceutical Drug Development Database

R D Focus. This database service [66] provides information on over 7000 drugs in active development. The service monitors the development, efficacy, and status of pharmaceuticals from early clinical testing through to launch. Data are gathered through direct contact with manufacturers and research organizations. It appraises both the scientific and commercial aspects of drug development and is searchable by product, by phase, by mechanism of action, and by country. R D Focus product is commercially available in several formats. 

Finally, the fourth element is a widened scope of application. The fact that LC/MS is now routinely used during every stage of drug development is a powerful benchmark for acceptance. The increased performance of applications that incorporate LC/MS have, in turn, stimulated new performance levels for sample preparation, high speed separations, automated analysis, information databases, and software tools, to name a few. Motivated by unmet industry needs, the drive for new applications has stimulated tremendous growth in pharmaceutical analysis marked by invention and creativity. 

Carlson SP, Ragueneau-Majlessi I, Levy RH. Development of a metabolic drug interaction database at the University of Washington. In Rodrigues AD, ed. Drugs and the Pharmaceutical Sciences, vol. 116. New York Marcel Dekker Inc, 2002 549-563. 

The interest in the present pharmaceutical industry is very wide spanning the overall drug discovery sphere encompassing data related to small molecules, structure activity relationships, pre-clinical candidates, clinical candidates, launched drugs, biomarkers, toxic molecules, and other target protein inhibitors. While no single database could address all these areas, attempts were made to at least address them individually. We have developed databases... 

SOURCE Office of Technology Assessment, 1993, based on data supplied by Tufts University Center for the Study of Drug Development from its database of NCEs reported by 41 pharmaceutical firms. 

As the twentieth century came to a close, the job market for computational chemists had recovered from the 1992-1994 debacle. In fact, demand for computational chemists leaped to new highs each year in the second half of the 1990s [135]. Most of the new jobs were in industry, and most of these industrial jobs were at pharmaceutical or biopharmaceutical companies. As we noted at the beginning of this chapter, in 1960 there were essentially no computational chemists in industry. But 40 years later, perhaps well over half of all computational chemists were working in pharmaceutical laboratories. The outlook for computational chemistry is therefore very much linked to the health of the pharmaceutical industry itself. Forces that adversely affect pharmaceutical companies will have a negative effect on the scientists who work there as well as at auxiliary companies such as software vendors that develop programs and databases for use in drug discovery and development. 

---